Good
Mostly Aligned
Patient Risk:
Low
Summary
Claims about indications, dementia-related psychosis non-approval, NMS discontinuation guidance, suicide-related adverse events, and associated monitoring are largely consistent with the provided label excerpts; main limitation is a potential context/wording mismatch regarding the suicide monitoring language being specific to antidepressant-treated patients (Section 5.2).
Category Scores
Accurate Statements
VRAYLAR is indicated for treatment of schizophrenia in adult and pediatric patients 13 years of age and older.
Section 1: “Treatment of schizophrenia in adult and pediatric patients 13 years of age and older”.
VRAYLAR is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older.
Section 1: “Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older”.
VRAYLAR is indicated for treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients.
Section 1: “Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients”.
VRAYLAR is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patients.
Section 1: “Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patients”.
VRAYLAR is not approved for the treatment of patients with dementia-related psychosis.
Sections 5.1 and 5.3: “VRAYLAR is not approved for the treatment of patients with dementia-related psychosis”.
Antipsychotic drugs increase all-cause risk of death in elderly patients with dementia-related psychosis, and the label warning applies to VRAYLAR.
Section 5.1 includes the mortality description and “VRAYLAR is not approved for the treatment of patients with dementia-related psychosis”.
If neuroleptic malignant syndrome (NMS) is suspected, immediately discontinue VRAYLAR and provide intensive symptomatic treatment and monitoring.
Section 5.4: “If NMS is suspected, immediately discontinue VRAYLAR and provide intensive symptomatic treatment and monitoring.”
Reported adverse events include suicide ideation, completed suicide, and suicide attempts.
Section 6.1: “Infrequent: suicide ideation; Rare: completed suicide, suicide attempts”.
Unsupported Statements
Contradictions
Low
AI Statement
VRAYLAR is approved for treatment of patients with dementia-related psychosis.
Label Reference
Sections 5.1 and 5.3: “VRAYLAR is not approved for the treatment of patients with dementia-related psychosis”.
Important Omissions
No evaluation of dosage and administration details was possible because the provided AI claims did not include dosing, administration, titration, or formulation-specific instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clear mismatch is an assertion that VRAYLAR is approved for dementia-related psychosis, which conflicts with the label (not approved). Other safety-related claims (NMS discontinuation, suicide-related adverse events, and monitoring concept) align with the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
A contradictory claim that VRAYLAR is approved for dementia-related psychosis (label states not approved).
Suggested Improvement
Remove/replace the contradictory approval statement and precisely mirror the label’s non-approval language for dementia-related psychosis; additionally, ensure suicide monitoring wording is not generalized beyond the label’s framing of monitoring antidepressant-treated patients.